Drug intelligence / Profile preview

AD-118

Development stage: Phase 1
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-118 is an incrementally modified drug (IMD) formulation of the combination sacubitril and valsartan, developed by Addpharma Inc. for the treatment of chronic heart failure. It belongs to the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) class. Sacubitril is a prodrug that, upon activation to sacubitrilat, inhibits the enzyme neprilysin, thereby increasing the levels of beneficial natriuretic peptides. Valsartan is an angiotensin II receptor blocker (ARB) that inhibits the renin-angiotensin-aldosterone system by antagonizing the AT1 receptor. This dual mechanism of action promotes vasodilation, natriuresis, and diuresis while inhibiting maladaptive cardiovascular remodeling, making it a potent therapy for managing heart failure symptoms and reducing cardiovascular mortality.

Brand names: Entresto
Other names: sacubitril + valsartan

Targets

NEP (Neutral Endopeptidase)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on AD-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-118.

Explore the full profile